Neurogenic stress cardiomyopathy (NSC) is defined as transient cardiac dysfunction occurring after primary brain injury, such as aneurysmal subarachnoid haemorrhage, and characterised by left ventricular systolic dysfunction with reduced ejection fraction and abnormalities of regional wall motion. It may also be suspected if elevated levels of cardiac biomarkers and ECG abnormalities are present. It is a reversible condition with favourable long-term prognosis if diagnosed and treated timely, however, NSC is associated with higher rates of early mortality and complications, including pulmonary oedema, cardiogenic shock, delayed cerebral ischaemia. Early diagnosis of the NSC is important in order to prevent these complications and reduce mortality. Management of the NSC is complicated and a multidisciplinary approach is usually required.
Introduction
Aneurysmal subarachnoid haemorrhage (aSAH) is a type of haemorrhagic stroke which occurs due to a ruptured intracranial aneurysm [1] . aSAH has an incidence of 6.3 per 100 000 persons per year in Europe and accounts for 5% of all strokes. High mortality rates, poor functional outcomes, high disease-specific burdenthese are the terms associated with aSAH [2, 3] . While the mentioned issues are widely recognized, aSAH may also cause cardiac dysfunction: ECG changes, cardiac arrhythmias, elevated cardiac biomarkers, left ventricular dysfunction [4] . Pathophysiology is mostly explained by massive catecholamine release, resulting in myocardial injury [5] . Cardiac abnormalities can occur alone or be a part of the disease called neurogenic stunned myocardium or neurogenic stress cardiomyopathy (NSC), some articles even use the name of Takotsubo-like cardiomyopathy [6] . It is unclear if we can use NSC as a synonym of Takotsubo cardiomyopathy or these definitions are different and should not be mixed. Takotsubo cardiomyopathy, which is transient and typically precipitated by acute emotional stress, is also known as "stress cardiomyopathy" or "broken-heart syndrome". Takotsubo cardiomyopathy mimics acute coronary syndrome and is accompanied by reversible left ventricular apical ballooning in the absence of angiographically significant coronary artery stenosis [7] . Both diseases are followed by left ventricular (LV) systolic dysfunction, changes on ECG and release of cardiac biomarkers [8] . Takotsubo cardiomyopathy usually occurs after an emotional stress event while NSC occurs after a primary neurological event, e.g. aSAH, and manifests with chest pain and clinical signs of heart failure with neurological damage [9] . Studies show that NSC is related to higher in-hospital mortality after aSAH [10] . For-tunately, NSC can be reversed if diagnosed on time, this is why it is important to review the data on the matter. In this review, we will focus on pathophysiology, clinical features, functional outcomes, and management of aSAH induced cardiac dysfunction.
Methods
MEDLINE database and PubMed search system were used for this review. The following words and phrases, as "neurogenic stress cardiomyopathy", "takotsubo-like cardiomyopathy", "subarachnoid haemorrhage", "stroke", "cardiovascular", "cerebrovascular diseases" were used for the search. We searched and evaluated review studies, observational and randomised clinical trials, case reports, published in English until April 2019.
Results

Subarachnoid haemorrhage and neurogenic stress cardiomyopathy
Acute central nervous system lesions can induce sudden cardiac dysfunction for patients with no prior underlying cardiovascular disease and contribute to higher in-hospital mortality rates and poor outcomes [11] [12] [13] [14] . Particularly, spontaneous acute aSAH is known to trigger abnormal heart conduction manifestations [15] . The relationship of these ECG abnormalities and cardiac rhythm disturbances with NSC was found out only later on [6] . The currently reported prevalence of NSC among aSAH patients range from 2.2% to 17% [12, [16] [17] [18] [19] [20] . Brain injury (autonomous nervous system damage in supramedullar or medullar regions) during an acute neurological event is the main factor for the development of subsequent cardiac manifestations. Insular cortex injury or hypothalamic damage due to increased intracranial pressure accompanied by direct extravasated blood pressure to hypothalamus can initiate a catecholamine release overdrive [11, 21] .
Catecholamine outburst and cardiotoxicity
The most acceptable current evidence-based theory of NSC heavily relies on catecholamineinduced myocardial injury [21] [22] [23] . A large amount of locally excreted catecholamines bind to cardiac adrenoreceptors and induces cardiomyocytolysis because of calcium overflow into cells, that, in turn, causes specific cell injury, including contraction band necrosis (due to reperfusion in hyper concentration condition) [23, 24] , monomorphonuclear cell infiltration, and the histopathologic picture, that is quite distinct from coagulation necrosis in acute myocardial infarction [24] . Myocardium ischaemic alteration is observable only hours to days after the acute coronary event when cardiac cell death occurs [25, 26] . In comparison, NSC myocytolysis takes place shortly after the catecholamine rush and becomes noticeable 5 minutes after the onset of aSAH [6, 27] . Catecholamine plasma serum concentration peak correlates with the level of heart injury biomarkers: i.e. peak elevation of Troponin T and CK-MB [6, 27] . Secreted local acting catecholamines, rather than circulatory, are responsible for myocardial injury in NSC [28] . During the intracranial injury, local catecholamines are released from cervical sympathetic ganglia through cardiac nerves and sympathetic plexus nerve endings. Sympathetic heart denervation as demonstrated in an experimental baboon model by Novitzky et al. can ultimately abolish heart response to brain lesions [28] . Following the same logic heart recipient patients unfortunate enough to experience aSAH, should evade NSC because of heart denervation effect that they received during transplant surgery. Catecholamine cardiotoxicity is highly involved in the pathophysiologic mechanisms of NSC.
Similarities with Takotsubo cardiomyopathy
A similar pathophysiology mechanism is responsible for Takotsubo cardiomyopathy [7] but NSC and Takotsubo differ by primary cause, the first one develops due to a neurological event and the second one takes place under emotional stress [9] . There is no consensus on the matter. Some authors suggest that this is the same disease with the same outcomes, others classify Takotsubo as primary stress cardiomyopathy and NSC -as a secondary stress cardiomyopathy [7] , and others declare these as two distinct conditions. Nevertheless, there is a lack of studies that would actually compare these two patient groups and present the answer. One study by Ancona et al. reported clinical differences between Takotsubo and NSC. A study shows that NSC clinical signs are more commonly present as heart failure, rather than acute coronary syndrome as it is in Takotsubo cardiomyopathy. Furthermore, patients with NSC have a lower level of cardiac biomarkers and, most importantly, regional wall motion abnormalities (RWMA) are more present in the basal segment rather than apical, as it is in Takotsubo cardiomyopathy [8] .
ECG abnormalities and rhythm disorders
The development of cardiac complications after aSAH can result in ECG changes as well as cardiac arrhythmias [8, 29] . ECG changes after aSAH can be found in up to 98% of patients [15, 30, 31] , including ST-segment and T-wave abnormality, the presence of U wave, P wave abnormalities, and prolonged QTc interval that are common and often seen early after haemorrhaging into subarachnoid space [32] . According to Ahmadian et al. the most common ECG abnormalities for patients with NSC are T wave inversion -17.2%, ST interval depression -13.8% and prolonged QT interval -10.3% [33] . The prevalence of heart rhythm disorders ranges from 50% to 90% of patients [34, 35] . The data concerning the prevalence differ depending on the study. The most common disorders include sinus tachycardia, sinus bradycardia, atrial fibrillation and atrioventricular block [34] [35] [36] . Although the majority of the occurring arrhythmias are mostly benign, up to 5% can be clinically significant and life-threatening [37] . Usually, ventricular or atrial fibrillation may develop within the first 2 days after aSAH [38] . These ECG changes and rhythm disturbances after aneurysmal subarachnoid bleed are related to a poor functional outcome, longer hospitalisation period and higher in-hospital mortality rate [39] . These ECG findings are not specific for this cardiomyopathy, and it is important to take into account clinical case presentation and the data of diagnostic modalities, in order to establish the diagnosis of NSC. Nevertheless, we should keep in mind and expect heart electrophysiological changes since NSC patients are more prone to develop them after a cerebral aneurysm rupture [30] .
Cardiac markers in blood serum
Troponin (Tn) consists of three subunits -I, T and C, that are a part of skeletal and cardiac muscle filaments. For nearly 25 years, two of these troponin isoforms (I and T) are being used in every day clinical practice to diagnose diseases involving cardiomyocyte death. Cardiac troponin I (cTnI) and troponin T (TnT) are useful in diagnosing NSC and predicting outcomes for patients after aSAH [40] . During initial 24-48 hours after aSAH, cTnI levels can peak above the limit (>0.1 ng/ml). This clinical phenomenon is common in 20-40% of aSAH patients and most of them do not have a coronary artery disease (CAD) [41] . cTnI serum concentration elevation has an important prognostic value for in-hospital mortality, hospital stay length, echocardiographic abnormalities and prediction of NSC. The patients with very high cTnI (>1.0 ng/ml) levels have higher in-hospital mortality rates that reaches up to 40% in comparison with 11% for patients with mild or low cTnI levels after aSAH [42] . A prospective study by Tanabe M. et al. found that patients with high levels of cTnI (>1.31 ng/ml) were more associated with prolonged hospital stay than those with mild or low levels of cTnI (14 vs 11 days respectively). Moreover, the study established that high levels of cTnI could predict abnormal heart wall motion in echocardiography with a 76% sensitivity and 91% specificity [43] . Abnormal regional wall motion is one of the cardiac abnormalities occurring in NSC, this means that cTnI, in a way, can help suspect RWMA. Furthermore, elevated cTnI levels predict poor functional outcomes after aSAH alike [44] . Another troponin isomere -hsTnT (high sensitivity troponin T) enables to detect NSC, also. A study by Oras et al. established that hsTnT peaked over 89 ng/l within 48 hours after the initial subarachnoid bleed, thus predicting NSC (sensitivity -100%, specificity -79%). The same study discovered that N-terminal pro B type natriuretic peptide (NT pro-BNP) could even be a better early marker for NSC [45] . NT pro-BNP is a heart marker, used in clinical practice for evaluation of heart failure, caused by left ventricular dysfunction [46] . In aSAH patients, the early increase of NT pro-BNP levels above 2.615 ng/l is correlated with the onset of pulmonary oedema, myocardial necrosis, systolic and diastolic dysfunction of the left ventricle, therefore, NT pro-BNP can be used as a promising NSC biomarker [47] . Both markers can be used to predict heart complications and outcomes after aneurysmal subarachnoid bleeding. Early biochemical cardiac marker increase can help suspect NSC and allow practitioners to start treatment timely.
Echocardiographic left ventricular dysfunction
NSC occurs as transient left ventricular (LV) systolic dysfunction early after aSAH and is described as an abnormal myocardium wall motion and reduced global ejection fraction (EF) [48] . RWMA may be present from 10% to 36% of cases in patients with NSC. Usually, LV systolic dysfunction impairs the basal and midventricular segments of the anterior and anteroseptal walls [49, 50] . RWMA is associated with higher mortality, with a relative risk of 1.9 [39] . As reported by Sugimoto et al. the reduction of LV ejection fraction (below 50%) was observed in up to 62% of patients. However, the average LV EF of all patients was approximately 40% [49, 51] . A study by Ahmadian et al. reported similar prevalence: 55.7% of patients had LV EF between 40-60%, and only 6.6% of patients had LV EF lower than 40% [33] . These two features, causing LV systolic dysfunction, may be isolated or present both. LV systolic dysfunction can result in systemic complications, pulmonary oedema, cardiogenic shock and it places patients at risk for cerebral ischaemia, putting NSC as a significant risk factor for mortality in aSAH patients. NSC accompanying acute brain injury is responsible for high mortality during hospitalisation (NSC 46.9% vs non-NSC 11.2%) [19] . However, reduced LV EF and RWMA are reversible and improvement of these echocardiographic findings are reported after a few follow-up weeks in NSC patient group [18, 48] . Up to 66% of the NSC patients have a full or partial recovery of LV systolic function [48] .
Diagnostic approach
As it was mentioned previously, elevated levels of troponin, serum cardiac natriuretic peptides, ECG abnormalities, and echocardiographic changes might presume NSC after aSAH diagnosis. Cardiac markers and ECG should be evaluated on admission and echocardiographic evaluation should follow if cardiac markers are elevated or ECG abnormalities are observed [52] . Additionally, acute coronary syndrome should be ruled out, since elevated troponin levels and signs of myocardial ischaemia are not NSC specific [12, 41 ]. Although, it is important to note that lower troponin and higher BNP blood serum levels are more frequent in NSC after subarachnoid haemorrhaging distinguishing them from acute coronary syndrome (ACS) patients [53] . In order to differentiate, early coronary angiography or cardiac magnetic resonance imaging (cMRI) might be the best option but it should be considered responsibly since coronary angiography is not recommended after aSAH routinely [12, 54] .
The most common major complications of NSC are acute heart failure, accompanied by cardiogenic shock, ischaemic stroke, arrhythmias, myocardium apical thrombosis and ventricular rupture [54, 55] . Since ECG changes often develop within the first three days after aSAH, continuous ECG monitoring should be provided for at least 72 hours after admission [48, 56] . Cardiac markers (BNP and Tn) should be repeated. BNP serum concentration increases soon after a subarachnoid bleed and returns to baseline within 2 weeks [23] . Elevated troponin levels were noticed in the first 72 hours likewise [57] . Continuous haemodynamic monitoring with a Swan-Ganz catheter should be considered in order to achieve appropriate measurement of central venous pressure [58] . In case NSC is suspected, a higher level of intensive care management by an interventional neurologist, a neurosurgeon, a cardiologist, and an intensive care practitioner should be carried out. Summary of diagnostic approach is demonstrated in Fig. 1 and typical case presentation is showed in Fig. 2 .
Neurogenic stress cardiomyopathy treatment
While haemodynamic augmentation, described as triple-H therapy (treatment of hypertension, hypervolemia and haemodilution), has been a mainstay in the management of ischaemic cerebral conditions. Fluid balance, β-blockers, inotropes and an intra-aortic balloon pump (IABP) are used for the treatment of NSC after aSAH [52, 58] . It is important to optimise cardiac output, maintain euvolemia and avoid hypotension in order to prevent complications including delayed cerebral ischaemia [19] .
β-blockers are considered to lower the risk of developing NSC by preventing the elevation of cardiac enzymes, development of arrhythmias and ECG abnormalities [5, 59, 60] . In the acute phase, β-blockers may be useful to reduce basal hypercontractility and increase cardiac filling, additionally lowering cardiac rupture risk [61, 62] . Despite this, recurrent NSC developed in 32.5-50.9% of the patients using β-blockers, but cardiac involvement was minor comparing to the first event. This means β-blockers are not effective in prevention of repetitive NSC but these medi-cations may mitigate the clinical manifestations [54, 63] . There is some data that combined use of angiotensin converting enzyme (ACE) inhibitors and β-blockers tends to be an effective therapy preventing from recurrence of NSC [7] .
Haemodynamic stability that is related to adequate cerebral perfusion and prevention for delayed cerebral ischaemia, might be maintained by means of vasopressors or inotropes. For example, using such vasopressor as phenylephrine, an α 1 -adrenergic receptor selective agonist, may be an option for hypotension treatment in patients with aSAH who do not tolerate fluid management or β-blockers resulting in an increased afterload and LV cavity size [7] . In the presence of LV dysfunction, haemodynamic instability and cardiogenic shock, such inotropes as dobutamine or milrinone might optimize the mean arterial pressure and cerebral perfusion pressure [56] . If dobutamine and milrinone are ineffective, levosimendan in comparison to β-agonist or phosphodiesterase inhibitor action on circulatory system may increase heart contractility and induce a vasodilatatory effect, resulting in improvement of organ hypoperfusion [64] .
In patients with left ventricular outflow tract obstruction manifesting as hypotension, intravenous inotropes should be avoided and treatment using β-blockade and IABP should be then preferred [65, 55] . Difficulties to achieve the blood pressure goals for haemodynamic augmentation because of low cardiac output are reported. In this situation, increased doses of inotropes and vasopressors could worsen hypotension and can determine secondary brain injury [51] . When high doses of vasopressors and inotropes are ineffective, the management using IABP may be indicated [56] . Usually, while using IABP, the demand for vasopressors decreases for mean of 50% within the first or the second day after initiation. Duration of IABP use ranges from 1 to 7 days (mean 4 days), resulting in normalized cardiac enzymes and function [66] . Despite high morbidity and mortality, NSC management is mainly supportive and symptomatic, based on the treatment of life-threatening events and there are no available clinical management and specific treatment recommendations so far [67] . Summary of possible treatment is presented in Fig. 1 .
Follow-up of left ventricular dysfunction
Recurrence of cardiomyopathy has been observed within the first year (average of 3 months) and no deaths after discharge were due to cardiac causes, suggesting that comorbidities are main predictors of mortality in these patients [68] . However, it is still important to follow-up the LV systolic function. Steady LV EF and RWMA im-e-ISSN 1822-7767 provement was observed since the 1 st to the 3 rd week after the onset of aSAH [63, 69] . Usually, the function of LV improves in a week. Therefore, it is recommended to repeat echocardiogram after 1 or 2 weeks after admission and perform the examination again, after 4-5 weeks following clinical recovery [48, 53, 56, 70] .
Conclusions
Catecholamine outburst after aSAH causes cardiac abnormalities. These include ECG changes, life-threatening arrhythmias, elevated cTn and NT pro-BNP levels, which can appear and predict NSC and its prognosis. Subarachnoid bleeding can also cause LV systolic dysfunction which can confirm the diagnosis of NSC. Management of the NSC is difficult and personalised treatment by a multidisciplinary team is required. More studies are needed for a better understanding and achieving universal NSC diagnostic algorithm as well as treatment options in order to prevent complications and reduce mortality.
